- Title
- IL-33 in chronic respiratory disease: from preclinical to clinical studies
- Creator
- Donovan, Chantal; Hansbro, Philip M.
- Relation
- NHMRC.1120152 http://purl.org/au-research/grants/nhmrc/1120152
- Relation
- ACS Pharmacology & Translational Science Vol. 3, Issue 1, p. 56-62
- Publisher Link
- http://dx.doi.org/10.1021/acsptsci.9b00099
- Publisher
- American Chemical Society
- Resource Type
- journal article
- Date
- 2020
- Description
- IL-33 has been deorphanized as a member of the IL-1 family and has key roles as an alarmin and cytokine with potent capacity to drive type 2 inflammation. This has led to a plethora of studies surrounding its role in chronic diseases with a type 2 inflammatory component. Here, we review the roles of IL-33 in two chronic respiratory diseases, asthma and chronic obstructive pulmonary disease (COPD). We discuss the hallmark and paradigm-shifting studies that have contributed to our understanding of IL-33 biology. We cover animal studies that have elucidated the mechanisms of IL-33 and assessed the role of anti-IL-33 treatment and immunization against IL-33. We highlight key clinical evidence for the potential of targeting increased IL-33 in respiratory diseases including exacerbations, and we outline current clinical trials using an anti-IL-33 monoclonal antibody in asthma patients. Finally, we discuss some of the challenges that have arisen in IL-33 biology and highlight potential future directions in targeting this cytokine in chronic respiratory diseases.
- Subject
- IL-33; anti-IL-33; ST2; eosinophils; asthma; COPD; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1436039
- Identifier
- uon:39902
- Identifier
- ISSN:2575-9108
- Language
- eng
- Reviewed
- Hits: 1659
- Visitors: 1655
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|